author-photo

Sergio Ortiz-Espinosa

University of Navarra

11

Papers

251

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (3)
FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.

2021 Journal of Hepatology
Show All
- Source
- Cite
- Save
Citations (1)
FP03.04 Dasatinib Improves the Antitumor Activity of Anti-PD-1 in NSCLC Models by Inhibiting Treg Conversion and Proliferation

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells.

2020 Cancers
Show All
- Source
- Cite
- Save
Citations (1)
Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

2020
Show All
- Source
- Cite
- Save
Citations (12)
Complementing the Cancer-Immunity Cycle

2019 Frontiers in Immunology
Show All
- Source
- Cite
- Save
Citations (57)
Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects

2018 American Journal of Respiratory and Critical Care Medicine
Show All
- Source
- Cite
- Save
Citations (35)
P3.07-007 Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A Combined PD-1/C5a Blockade Synergistically Protects Against Lung Cancer Growth and Metastasis

2017 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (85)
Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatment

2017 Seminars in Cell & Developmental Biology
Show All
- Source
- Cite
- Save
Citations (47)